Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Right now!
CNBC just announced that coach Jim Boeheim will be featured on Squawk Alley. Does anyone think he will mention CTIX??
New $MJNA Article: Medical Marijuana, Inc. And Next Galaxy Form The New Reality
The medical and therapeutic properties of marijuana in the United States has been recognized since 1850, when it even merited an entry into the1850’s edition of the medical reference book, United States Pharmacopeia. Its role in society nevertheless has been mired in social and political controversy and has over the decades conflicted with the federal government’s drug laws. However, through much effort and determination of its many proponents, and the success of states referendums, as many as 23 states have legalized, or are preparing to legalize, medical marijuana. This development has created new opportunities for companies in the bio-medical field to provide products and services for this emerging market. One of the companies is Medical Marijuana, Inc. (MJNA).
Legal Highs
Medical Marijuana, Inc., as the name suggests, provides products and services for the medical marijuana and industrial hemp markets. The company is located in San Diego, CA and recently announced in its first quarter report a high of $4 million in sales, about $2 million higher than previous quarter. Under the company banner is also HempMedsPX, which provides marketing and logistics for the cannabis industry; CanChew Biotechnologies focusing on the treatment of medical disorders and pain with the use of chewing gum-based cannabis; Wellness Managed Services, provider of management support for wellness facilities; and MPS International, security services to businesses in the legal cannabis industry.
For investors though, Medical Marijuana, Inc. can be seen as akin to a pot mutual fund in that the company owns various sectors of the marijuana market including the growing and selling of it as well as the peripheral side streets of marketing and management support. Of course, it is by no means the only marijuana company to spring up during the legalization bubble, but it is one with foundational roots with both knowledge and experience in the industry. The company has a 52-week trading range of between $.09 and $.48. According to the company’s 2013 Fourth Quarter Shareholder’s Report, its HempMedsRX posted revenues of $1.4 million, higher than that of $250,000 posted in the third quarter. Under its CanChew Biotechnologies segment, the company posted fourth quarter sales of $58,000, up from $34,000 in the third quarter. MJNA’s Red Dice Holdings stated reported fourth quarter income of $434,000, slightly higher than its third quarter income of $322,000. Red Dice Holdings is also the owner of Dixie Brand which includes Dixie Botanicals that provides 70 unique consumer products.
MJNA had roughly $2.7 million in cash at the beginning of 2014, after burning through about half of its reported sales revenue. The company’s debt is kept low with management’s tight reins on operating costs. The company has a market cap of $146 million, revenue of 7.42 million, and total debt of $6.88 million. With the selloff of cannabis stocks in the first quarter, there was no shortage of stock shares. Currently, MJNA has a diluted EPS of 0.03 and the need for diluting is negated by the increase in quarterly earnings (142% year-over-year), and strong or growing foundational numbers.
With the company’s first quarter earnings jump and the increasing popularity of marijuana use, (some speculate that other states will legalize marijuana use before Obama’s term ends), I see Medical Marijuana, Inc. as attractive now while it is cheap and holding on to it for future highs. However, I caution investors that this is speculative and still risky as the industry is far from mature as legislation is still being formed.
Medical Marijuana & Virtual Reality
Remarkably, emerging at the same time, which may cut into the growth of medical marijuana, is the world of Virtual Reality. It is an immersive medium, which is a computer-simulated environment that can simulate physical presence in places in the real world or imagined worlds.
Treatments that have been proposed for various medical issues such as anxiety and depression by the medical marijuana industry have been gaining traction in the virtual reality space as well. Virtual Reality based therapies is a means of providing controlled stimuli with the therapist able to monitor the patients reaction. This therapy was jump-started with the help of DOD funding with military labs setting up virtual reality treatment centers for treating PTSD and a variety of other medical conditions.
Facebook's $2.4 Billion Virtual Reality Acquisition
As virtual reality becomes mainstream with Facebook’s (FB) $2.4 billion dollar acquisition you will see more companies with virtual reality platforms move into the medical space. Microsoft (MSFT) is developing a virtual reality gaming platform that is in the works according to Microsoft Studio boss Phil Spencer. Additionally, Next Galaxy Corporation (NXGA) recently signed with EON Reality and Willie “BumBum” Baker to develop fully immersive entertainment platforms that allow you to be at various places without actually, physically being there using virtual reality hardware. Subsequently, due to the Facebook acquisition it is wise to watch for this sector to start garnering heavy attention in the near term. It may be prudent to get in early before the release of Facebook's Oculus Rift.
Conclusion
Growth is expected to continue for Medical Marijuana as more states legalize marijuana. However, it will be interesting to note the long term effect of virtual reality on the medical marijuana field as virtual reality becomes more mainstream for treatments of depression and anxiety. It also may be the combination of legalized marijuana and virtual reality to be a winning combination with each industry working in sync with one another.
Read more: http://www.benzinga.com/14/08/4798634/medical-marijuana-inc-and-next-galaxy-form-the-new-reality#ixzz3B8utTYnn
New $INO Article Three Biotech Companies With Disruptive UPenn Technologies Nearing Major Catalyst
The University of Pennsylvania (UPenn) is one of America’s most premiere Ivy League research universities. Its place as a home of innovation can be traced back to its founder Benjamin Franklin who advocated an educational program that focused as much on practical education for commerce and public service as on the classics and theology. UPenn is also home to the first medical school and business school in North America. UPenn is among the top five research centers in the United States and in the world. Their academic research spending tops any Ivy League school in America with an $814 million dollar budget. In only the last ten years there have been nine members from UPenn that won a Nobel Prize. While UPenn’s history of innovation and development is impressive its latest biotech discoveries are revolutionary. What follows are three biotech companies with disruptive technologies nearing major catalysts which may offer investors above average returns.
Novartis: Programmed Killer T-Cells
CTL-019 was invented by UPenn’s famous researcher named Dr. Carl June and is now being developed by Novartis (NVS). Dr. June has done what no other researcher has done before – programed cancer killing T cells to wipe out the cancer and to then leave a population of memory cells that can be reactivated whenever cancer presents itself. CTL019 uses CAR technology to reprogram a patient's own T cells to "hunt" cancer cells that express specific proteins, called CD19. After they have been reprogrammed, the T cells (now called CTL019) are re-introduced into the patient's blood; they proliferate and bind to the targeted CD19+ cancer cells and destroy them.
Keep an eye on this treatment as it has just won the FDA’s coveted breakthrough designation in June and has been showing success in clinical trials. In a Phase 2 clinical trial 7 adult patients with CLL (chronic lymphocytic leukemia) experienced complete remission of their disease and 19 pediatric patients with ALL (acute lymphoblastic leukemia) experienced complete remissions. Staying up on CTL019 is wise as results are expected on their Phase 2 clinical trial.
Difensin Mimetics - A Powerful Multi Use Superbug Killer
Cellceutix Corporation (CTIX), a company that is now starting to gain the industry’s attention, licensed from UPenn a revolutionary new class of antibiotics called Defensin Mimetics, small-molecules that imitate natural human immunity. In a way, a similar idea is to have the body “hunt” the bacteria, but doing it with synthetics. These new classes of antibiotics were developed by chemists at UPenn using sophisticated computers and complex 3-D software. Defensins are very novel in that they electrostatically lock onto bacteria and other microorganisms and effectively perforate their outer membranes. Whereas conventional antibiotics must penetrate bacterial cell walls, defensins act directly on the surface membrane. To escape the defensins, bacteria would have to evolve entirely new outer membrane characteristics. Defensin mimetics have also been found to have anti-inflammatory and immune-modulatory properties as well. Therefore they have the potential to be the breakthrough treatment addressing huge unmet markets such as Oral Mucositis and Diabetic Foot Ulcers.
Brilacidin, their leading defensing mimetic has just completed its Phase 2b trial for acute bacterial skin and skin structure infections (ABSSSI). What sets Cellceutix apart from other antibiotic companies is that in this Phase 2b trial, Cellceutix selected Cubist blockbuster daptomycin (Cubicin) for the comparator arm whereas the other antibiotic companies used vancomycin, a generic with growing resistance issues. Brilacidin is also being administered as a single dose regimen and a three day regimen versus standard seven day daptomycin therapy. If Brilacidin shows to be non-inferior to daptomycin in any dosing scheme and demonstrates to be safe and well tolerated, it will be a milestone moment in the world of antibiotics. Another gem that originated at UPenn.
The Father of DNA Vaccines
Inovio Pharmaceuticals, Inc. (INO) is a biopharmaceutical company that holds promising candidates in its pipeline for the treatment of cancer and infectious diseases. It is also carrying out research in proprietary technologies to develop new methods of vaccine delivery, design and formulation.
A lot of the technology for Inovio came from the work of Dr. David Weiner a world class researcher at UPenn. Dr. Weiner, also known as the father of DNA vaccines, discovered how to genetically engineer plasmids to produce any protein that is normally produced by our DNA. These plasmids can be engineered to make antigens which alert the immune system to the presence of a disease and activate an army of specific T-cells to attack the disease.
Inovio's leading vaccine VGX-3100 is used to treat cervical intraepithelial neoplasia (CIN), a disease leading to the abnormal growth of squamous cells on the surface of the cervix. Phase 2 trial results which have just been released in late July showed that treatment with VGX-3100, Inovio's HPV16/18-specific immunotherapy, resulted in histopathological regression of CIN2/3 to CIN1 or no disease, meeting the study's primary endpoint. In addition, the trial demonstrated clearance of HPV in conjunction with regression of cervical lesions. Robust T-cell activity was detected in subjects who received VGX-3100 compared to those who received the placebo. It is important to keep an eye on this company as the next catalyst may be positive communication with the FDA to advance VGX-3100 in clinical trials.
Read more: http://www.benzinga.com/14/08/4790560/three-biotech-companies-with-disruptive-upenn-technologies-nearing-major-catalyst#ixzz3AvYLhgRt
SA Article: $ABX, $DTRC, $GSV, $NEM, $PGLC
SA Article: $ABX, $DTRC, $GSV, $NEM, $PGLC
SA Article: $ABX, $DTRC, $GSV, $NEM, $PGLC
SA Article: $ABX, $DTRC, $GSV, $NEM, $PGLC
Yes. Also gold up big today
Interesting Read: Gold Miners Feel Lucky in Search for Nevada Buried Riches
"......That explains why Goldrush remained undiscovered through multiple owners, including Homestake Mining Co., which found in the 1980s low-grade ore that couldn’t easily be processed then and discarded the prospect....."
Gets you thinking what else Homestake Co may have discarded....
http://www.bloomberg.com/news/2014-06-17/gold-miners-feel-lucky-in-search-for-nevada-buried-riches.html
Dakota Territory aims to have next Homestake mine;
on the acquisition trail
by Angela Kean
Dakota Territory Resource Corp. believes it could potentially develop another Homestake mine in the Black Hills region of South Dakota, with its landholding located on the same structural trend that hosts the former Barrick Gold Corp.-owned mine that produced 40 million ounces while it was in operation......
https://www.snl.com/InteractiveX/default.aspx
check their website and filings
Management is taking over where they left off when they led Homestake Mining Company successful multi million dollar mining exploration program in the 90's. It is one of the richest areas of gold in the world. They expect to start drilling soon from their releases.
5 Mining Companies Sitting On Billion Dollar Assets Ready To Move
http://seekingalpha.com/article/2211053-5-mining-companies-sitting-on-billion-dollar-assets-ready-to-move
Jonny Yates from Benzinga
$PPP 5 Mining Companies Sitting On Billion Dollar Assets Ready To Move http://seekingalpha.com/article/2211053-5-mining-companies-sitting-on-billion-dollar-assets-ready-to-move
$REE 5 Mining Companies Sitting On Billion Dollar Assets Ready To Move http://seekingalpha.com/article/2211053-5-mining-companies-sitting-on-billion-dollar-assets-ready-to-move
$PAL 5 Mining Companies Sitting On Billion Dollar Assets Ready To Move http://seekingalpha.com/article/2211053-5-mining-companies-sitting-on-billion-dollar-assets-ready-to-move
Homestake District or the Homestake Deposit, the 100-square-mile area yielded approximately 44 million ounces of gold in its 136-year-history
company owns land in the historic Homestake District of the northern Black Hills of South Dakota, an area that once produced the second largest amount of gold in U.S. history.
GO DTRC!!
Great interview Progressive!
It has to be MD Anderson! First one is being conducted at Dana Farber we all know they are the top! In the southwest the best is MD Anderson! Kevetrin is only going to go to the top hospitals!
CTIX is #3 most active board. See list below:
Top 10 Active Stock Market Forums
1. SRGE Southridge Enterprises, Inc.
2. AMBS Amarantus BioSciences Inc
3. CTIX Cellceutix Corporation
4. CIRC Cirtran Corp
5. BMSN Bio-Matrix Scientific Group Inc.
6. EEDG Energy Edge Technologies Corp.
7. MDIN Northstar Global Business Services, Inc.
8. GARB Garb Oil & Power Corp.
9. USGT USA Graphite, Inc
10. KMAG KMA Global Solutions International
Aspire Capital is adding to its portfolio!!! Yesterday they signed a $20 Million deal with Cyclacel Pharmaceuticals.
The company is now trading at $6.27!
Aspire only goes into good companies with strong upsides. That is why they invested in Cellceutix last week. They see a valuable company with a good pipeline.
http://finance.yahoo.com/news/cyclacel-enters-20-million-common-121500206.html
This is great news for cellceutix. This is an amazing deal! That is why the news came out today in the beginning of the week!!!!!
What company post bad news in the beginning of the week?? The fact of the matter is if this were bad news then they would have posted it 4PM Friday!
We should all be delighted by this deal!!
Congrads!!! We are finally over the $1.00 mark. Thanks all for hanging tight all this time!
I feel that everyone missed something important during the speech. After Leo mentioned about Dr. Reddy manufacturing Prurisol he said that they expect to start clinical trials in Europe..hmm.??
We hit the million share mark. Congrads!!!!
Dr F. in the press release Leo mentions
"we wish to test Kevetrin™ as a combination therapy for leukemia with drugs proprietary to one of the world’s largest pharmaceutical companies."
Wouldn't the large pharma company be the one picking up the tab for this? They are the ones with the big pockets and who is initiating the trial.
Over 500K shares today.
We are at 447K. Looks like its a record!!!
I believe it was 443,200 shares on May 27, 2011
Take a look cellceutix totally revamped their website.
http://cellceutix.com/
It looks really good!
As an investor in CTIX I dont see the reason to bother Dr. Shapiro the principle investigator at Dana Farber. I am certain you will first read about the start of dosing from a CTIX press release. These oncologist are so busy with patients and their families.
I just feel that the volume has picked up over the last few weeks as we have seen more ppl come on board learning about cellceutix. so y stop there!
Guys we already closing in on 100 followers and according to what doc mentioned the true # of ppl following are 1,000.
Does anyone have any good ideas of how to spread the word of cellceutix? How can we get the word out there? It seems everyone on this board found out about cellceutix from all diff ways.
any thoughts?
Yesterday I wrote to The Green Baron asking if they still feel the same way about CTIX. The original article was at
http://www.thegreenbaron.com/Cellceutix%20Analyst%20Discussion%20Newsletter%20Format.pdf
This is what they wrote back to me:
I spoke with my associate who follows Cellceutix extremely closely and is in contact with management on a regular basis. He is heavy in Cellceutix and believes that there is enormous potential because of the p53 connection with their lead compound, Kevetrin. His words to me (and he emphasizes that he is not an investment advisor or doctor and that all commentary is merely his opinion):
“There can always be comparisons drawn with a company like Pharmasset because they seem to have a very special drug for Hep C, which represents a huge area of unmet medical need and has the potential to generate billions annually in revenue. Kevetrin is similar in the sense that scientists have been trying for decades to re-activate the p53 pathway because of its crucial role in controlling cell cycles and the fact that it is known to be damaged or mutated in nearly all cancers. The laboratory research certainly appears to show that they are closer than anyone else to tapping-into the power of the p53 pathway. Clinical trials are, of course, the key. IF (and in biotechnology that is the big word), Cellceutix can show safety while identifying dosing levels in the Phase I clinical trial and Dana-Farber and Beth Israel Deaconess and by some chance show some efficacy as a bi-product (efficacy is never a primary endpoint in a Phase I trial), it would be presumable that major pharma is going to start really honing-in on this small biotech. There’s not much more that can be said other than what is public. The facts are:
· Arguably the most well-recognized cancer research center in the world is hosting the trials. No biotech the size of Cellceutix has ever hosted trials there. The smallest one I could find had a market cap 5 times that of CTIX when the trials began. Dana-Farber doesn’t make it policy to just take cash to host trials. It would seem that they see something in Kevetrin’s data and profile.
· Beth Israel Deaconess has taken it upon themselves to contact Cellceutix about combination studies with Pfizer drugs (for which Beth Israel will be paying for the research). It would seem that they see something particularly impressive as well.
· Cellceutix CSO Dr. Krishna Menon played a key role in early development of Alimta and Gemzar (still two of the biggest cancer drugs in use today) while at Eli Lilly. He has said that he believes Kevetrin can be bigger than those two drugs combined. The whole Cellceutix team is excited about Kevetrin and has been for several years without the excitement ever waning. In fact it’s higher than ever at this point.
· Kevetrin has showed tumor growth delay and significant reduction in every cancer cell line that it has been tested on in pre-clinical studies. The range of cell lines has been broad, including lung, breast, leukemia, colon, prostate, head & neck and squamous cell carcinoma. The effectiveness would seem to be because p53 controls cell cycles across the body; it’s not specific to a certain cancer. While most other chemotherapies are basically a poison (for lack of a better word) begin injected into the body to destroy specific tumors, Kevetrin re-activates p53, allowing the body to naturally destroy the cells. In a sense, the tumors self-destruct. It’s similar to immunotherapies that are being heralded as the next great thing in cancer therapy, except Kevetrin is actually another step up on the immunology ladder as a top-tier defense system.
· Kevetrin has been shown to be non-genotoxic. When Roche came out with Nutlins, it was trumpeted as one of the biggest breakthroughs ever in cancer research because it re-activated p53. Unfortunately for Roche, Nutlins proved to be genotoxic, meaning that they destroyed DNA as well as tumors (obviously a bad thing). They are still researching Nutlins to this day because they know how huge it can be if they could just figure it out.
· The Cellceutix Senior Management and Advisors have built their reputations in senior management positions at some of the biggest and best oncology organizations in the world (Dana-Farber, Sloan Kettering, Pfizer, etc.). Those individuals with centuries of experience combined in cancer research have thoroughly reviewed all the data collected so far and commented several times on how impressed they are with Kevetrin. The leaders have a lot of skin in the game with funding the company on their own and never drawing a paycheck. The clearly believe in the big picture and where Cellceutix can be in a couple years.
· Non-Disclosure Agreements have been signed with “major pharmaceutical companies.” This is rare for a pre-clinical company to be approached by big pharma and indicates that majors already have their eyes on Cellceutix and want to see data as it is received before it goes public. Big pharma is notoriously bad at developing early-stage drugs and looks for acquisitions. This is especially true in today’s biotech space as the patent cliff has many of the big pharmas with thin pipelines. Add it Kevetrin showing robust anti-cancer activity and it bodes especially well for Cellceutix.
In my opinion, the company is heavily undervalued at this price point. Obviously, I am eager for the clinical trials to get underway and look forward to the first bits of data to be received. Biotech stocks are very cyclic with the commencement of clinical trials typically a point where price per share increases, so I am hoping for the same to happen with Cellceutix.”
Cellceutix interview was just posted on GuruFocus!
http://www.gurufocus.com/news/153170/interview-with-ceo-of-cellceutix-corporation-leo-ehrlich-
Lets all Rate the article 5 stars so we can get more publicity.
more publicity = more volume!
Lets start getting the price into the .60's